| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
LifeStance Health Group, Inc. Common Stock
$12.79
-0.05 (-0.39%)
Market Cap
4.95 B
EPS
0.13
P/E Ratio
96.26 $
Value Trade
126.55 M
4.3 %
Week
11.31 %
1 Month
70.84 %
3 Month
77.26 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
497.12 K
52 Week Range
4.77 - 12.85
% held by Insiders
36.23 %
% held by Institutions
63.09 %
Enterprise Value
5.05 B
Total Shares
388.14 M
Short %
4.84 %
Float Shares
197.95 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
LFST Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LFST
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LFST Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LFST
Aug 20, 2026▼ -0.4%today
LifeStance Health Foundation Renews Partnership with the American Foundation for Suicide Prevention to Advance Mental Health Research
LifeStance Health Foundation has renewed its partnership with the American Foundation for Suicide Prevention (AFSP), committing $100,000 to support clinical research aimed at advancing suicide prevention strategies. This partnership has already raised over $170,000 in its inaugural year, highlighting the urgent need for research in this critical area of mental health. LifeStance will continue to match teammate donations to AFSP, fostering further engagement in suicide prevention initiatives.
Read more →-LFST
Jul 16, 2026LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
LifeStance Health Group, Inc. will release its second quarter 2026 earnings before the market opens on August 6, 2026. The company will host a live conference call at 8:30 a.m. ET to discuss the results. Interested parties can join the call via phone or access a live audio webcast on the Investor Relations website.
Read more →-LFST
May 8, 2026▼ -13%on this news
LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group has announced the pricing of a secondary public offering of 35 million shares at $8.15 each. The offering will be conducted by selling stockholders, with LifeStance not selling any shares or receiving proceeds. Additionally, the company plans to repurchase 6 million shares from the underwriter, contingent on the offering's completion. The offering is expected to close around May 12, 2026.
Read more →-LFST
May 7, 2026▲ +20.2%on this newsshared move
LifeStance Reports First Quarter 2026 Results
LifeStance Health Group, Inc. reported strong financial results for Q1 2026, with a 21% increase in revenue to $403.5 million and a notable rise in net income to $14.2 million. The company also experienced significant growth in clinician numbers and visit volumes. LifeStance raised its revenue expectations for the full year 2026, indicating robust demand for mental healthcare services.
Read more →-LFST
May 7, 2026▲ +20.2%on this newsshared move
LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group has announced a secondary public offering of 35 million shares by certain stockholders. The company will not benefit from the proceeds, as they will go directly to the selling stockholders. Additionally, LifeStance has authorized the repurchase of 6 million shares, contingent upon the completion of the offering.
Read more →-LFST
May 7, 2026▲ +20.2%on this newsshared move
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports First Quarter 2026 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported strong financial results for the first quarter of 2026, with revenues reaching $403.5 million, marking a 21% increase year-over-year. Significant growth in net income and Adjusted EBITDA was noted, with net income jumping to $14.2 million from $0.7 million. The company raised its revenue expectations for the full year to between $1.640 billion and $1.680 billion, reflecting confidence in its business model and growth strategy. LifeStance also reported that approximately 75% of 180,000 patients in an outcomes study showed clinically significant improvements in anxiety and depression. The financial health of the company is robust, with solid cash flow and minimal long-term debt.
Read more →-LFST
Apr 29, 2026LifeStance to Present at Upcoming Investor Conferences
LifeStance Health Group, Inc. (NASDAQ: LFST) has announced its participation in two upcoming investor conferences. CEO Dave Bourdon will present at the Bank of America 2026 Healthcare Conference on May 13 and at the William Blair 46th Annual Growth Stock Conference on June 4. Both presentations will be webcast live and available for replay on the company's investor relations website.
Read more →-LFST
Apr 16, 2026LifeStance to Host First Quarter 2026 Earnings Conference Call on May 7, 2026
LifeStance Health Group, Inc. will release its first quarter 2026 earnings on May 7, 2026. A live conference call will be held at 8:30 a.m. ET to discuss the results. Participants can join via phone or through a webcast on the company's Investor Relations website. A replay will be available post-call.
Read more →-LFST
Feb 25, 2026LifeStance Reports Fourth Quarter and Full Year 2025 Results
LifeStance Health Group, Inc. announced its financial results for Q4 and full year 2025, highlighting significant revenue growth and a positive net income. The company ended the year with strong cash flow and announced a $100 million share repurchase program. CEO Dave Bourdon expressed optimism about the company's operational momentum heading into 2026.
Read more →-LFST
Feb 25, 2026Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2025 Results Announces $100 Million Share Repur
LifeStance Health Group, Inc. reported strong financial results for Q4 and the full year 2025, with a 17% increase in quarterly revenue and a significant rise in net income. The clinician base grew by 9%, contributing to higher visit volumes, which increased by 18% in the quarter. Looking ahead, LifeStance anticipates continued revenue growth in 2026, supported by an approved $100 million share repurchase program, reflecting confidence in its cash flow and financial health.
Read more →-LFST
Feb 10, 2026LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. will release its fourth quarter and full year 2025 earnings on February 25, 2026. A live conference call is scheduled for the same day at 8:30 a.m. ET, where results will be discussed. The call can be accessed via phone or through a webcast on their Investor Relations website.
Read more →-LFST
Nov 6, 2025▲ +29.9%on this news
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Third Quarter 2025 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported strong financial results for the third quarter of 2025, with revenue increasing by 16% year-over-year to $363.8 million. The company achieved a positive net income of $1.1 million, a significant recovery from a net loss of $6.0 million in the previous year. LifeStance also expanded its clinician base by 11%, reaching nearly 8,000 clinicians, and reported an increase in adjusted EBITDA of 31% to $40.2 million. The company reiterated its full-year revenue guidance while raising expectations for center margins and adjusted EBITDA.
Read more →-LFST
Aug 7, 2025Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Second Quarter 2025 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. announced its financial results for Q2 2025, showing an 11% increase in revenue to $345.3 million. The number of clinicians grew by 11%, and visit volumes rose by 12%. The net loss, however, was reduced to $3.8 million from $23.3 million in the previous year, highlighting operational improvements. The company also raised its full-year guidance for revenue and Adjusted EBITDA. Despite these gains, LifeStance faces ongoing challenges in a competitive and regulated healthcare industry.
Read more →-LFST
May 14, 2025LIFESTANCE
LifeStance Health has appointed Vaughn Paunovich as the new Chief Technology Officer, effective June 9, 2025. Paunovich, who has over 25 years of experience in health care technology, will spearhead LifeStance's technology strategy to enhance digital experiences for patients and clinicians. He replaces Pablo Pantaleoni, who played a significant role in the company's digital transformation. The transition reflects LifeStance's ambition to improve access to mental health services across the country.
Read more →-LFST
May 7, 2025▼ -15.9%on this news
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports First Quarter 2025 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported its first quarter 2025 financial results, highlighting a revenue increase of 11% to $333.0 million. The company achieved net income of $0.7 million, marking its first positive net income since becoming public, alongside a 10% increase in clinician numbers. However, the company also recorded negative cash flow from operations and free cash flow for the quarter. Looking ahead, LifeStance reaffirmed its revenue and EBITDA guidance for the fiscal year 2025.
Read more →-LFST
Feb 27, 2025LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman Ryan McGroarty to Become Chief Financial Officer
LifeStance has appointed Dave Bourdon as its new CEO, succeeding Ken Burdick who moves to Executive Chairman. Ryan McGroarty will serve as the new Chief Financial Officer. This leadership transition is positioned to continue the company's growth and operational excellence in outpatient mental health care, with Bourdon emphasizing a commitment to improving access to mental health services. The change is effective March 3, 2025, aligning with LifeStance's strategic objectives going forward.
Read more →-LFST
Feb 27, 2025Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2024 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. The company saw a 19% increase in total revenue compared to the previous year, reaching $1,251 million, while Adjusted EBITDA grew by 103%. Despite a net loss of $57.4 million for the year, LifeStance expanded its clinician base by 12% and is projecting continued revenue growth in 2025. Management emphasized a focus on enhancing access to affordable mental healthcare as they look ahead to the upcoming year.
Read more →-LFST
Nov 7, 2024▲ +7.7%on this news
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Third Quarter 2024 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. announced strong financial results for Q3 2024, with revenue growth of 19% year-over-year, totaling $312.7 million. The company also saw a substantial improvement in adjusted EBITDA, increasing to $30.7 million, and reported a net loss of $6.0 million, significantly better than the previous year's loss. The clinician base grew to 7,269, and patient visits rose by 15%, highlighting the company's expanding capacity to provide mental healthcare. LifeStance optimistically raised its full-year revenue guidance amid these improvements.
Read more →-LFST
Aug 8, 2024▲ +7.6%on this news
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Second Quarter 2024 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported financial results for the second quarter of 2024, showcasing a 20% increase in revenue year-over-year, totaling $312.3 million. The company also achieved a significant improvement in Adjusted EBITDA, which rose 103% to $28.6 million. While the net loss decreased from $45.5 million to $23.3 million, concerns around stock-based compensation remained evident. LifeStance has raised its revenue and margin expectations for the full year 2024, reflecting confidence in its ongoing operational performance.
Read more →-LFST
May 9, 2024Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports First Quarter 2024 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. announced its first quarter 2024 financial results, reporting a 19% increase in revenue to $300.4 million compared to the previous year. The company also saw a 15% rise in its clinician base, reaching a total of 6,866 clinicians and a significant increase in visit volumes. Adjusted EBITDA improved dramatically, increasing to $27.7 million, while the net loss was reduced to $21.1 million. Looking ahead, LifeStance reaffirmed its financial expectations for the entire year, highlighting expectations for revenue between $1.19 billion to $1.24 billion and positive cash flow.
Read more →-LFST
Feb 28, 2024▲ +30%on this news
Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2023 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported its financial results for the fourth quarter and full year of 2023, showing significant revenue growth with a 22% increase in Q4 and a 23% increase for the year. The company increased its clinician base by 18% and reported a substantial rise in adjusted EBITDA, highlighting strong operational performance. However, despite the revenue growth, LifeStance recorded a net loss largely attributed to expenses related to stock-based compensation and a settlement of a lawsuit. Looking forward, the company provided an optimistic guidance for 2024 with expected revenue growth and positive cash flow.
Read more →-LFST
Nov 8, 2023▼ -6.1%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Third Quarter 2023 Results SCOTTSDALE, Ariz. –
LifeStance Health Group reported its Q3 2023 financial results, showing a 21% increase in total revenue compared to the same period last year, reaching $262.9 million. Despite the revenue growth, the company incurred a net loss of $61.6 million, which was influenced by a shareholder lawsuit settlement and stock-based compensation expenses. The company has raised its guidance for full-year revenue and adjusted EBITDA, while also highlighting successful recruitment efforts that added nearly 300 clinicians. However, the increased operational losses signal ongoing challenges in maintaining profitability.
Read more →-LFST
Aug 9, 2023▼ -7.1%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Second Quarter 2023 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. (LFST) reported its Q2 2023 financial results, showcasing a 24% increase in total revenue to $259.6 million compared to the prior-year period. The company significantly reduced its net loss to $45.5 million from $68.7 million, despite a 3% decline in adjusted EBITDA. LifeStance raised its revenue and Center Margin guidance for the full year to reflect confidence in ongoing growth, while emphasizing the importance of expense management following increases in general and administrative costs.
Read more →-LFST
May 10, 2023Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports First Quarter 2023 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. has reported its financial results for the first quarter of 2023, showing a 24% increase in revenue to $252.6 million compared to the previous year. Despite the revenue growth, the company posted a net loss of $34.2 million. The company has raised its revenue and Center Margin guidance for the full year 2023, projecting revenues between $990 million and $1.02 billion. The results highlight both positive growth in total clinicians and the challenges faced in maintaining Adjusted EBITDA.
Read more →-LFST
Mar 8, 2023▲ +18.1%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2022 Results SCOTTSDALE, Ariz. –
LifeStance Health Group, Inc. reported its financial results for the fourth quarter and full-year 2022, highlighting a 21% revenue increase in Q4. The company's clinician base grew by 18%, underscoring demand for mental healthcare services. Despite positive adjusted EBITDA figures, LifeStance recorded a significant net loss driven mainly by compensation expenses. Looking forward, the company anticipates revenue between $980 million and $1.02 billion for 2023.
Read more →-LFST
Nov 8, 2022Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Third Quarter 2022 Results SCOTTSDALE, Ariz. –
Investor Relations Contact VP of Investor Relations investor.relations@lifestance.com LifeStance Reports Third Quarter 2022 Results SCOTTSDALE, Ariz. November 8, 2022 LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental heal
Read more →-LFST
Nov 3, 2022LIFESTANCE HEALTH APPOINTS J. MICHAEL BRUFF AS NEW BUSINESS TRANFORMATION OFFICER
LIFESTANCE HEALTH APPOINTS J. MICHAEL BRUFF AS NEW BUSINESS TRANFORMATION OFFICER; DAVID BOURDON AS CHIEF SCOTTSDALE, Ariz. - Nov. 3, 2022 LifeStance Health (NASDAQ: LFST), one of the nation s largest providers of outpatient mental healthcare, today announced that effective Nov
Read more →-LFST
Sep 8, 2022▲ +25.8%on this news
LifeStance Health Appoints Ken Burdick as CEO and Chairman; Founding CEO and Chairman Michael Lester Retires Danish Qureshi Named President in Addition to Role as Chief Operating Officer
LifeStance Health Appoints Ken Burdick as CEO and Chairman; Founding CEO and Chairman Michael Lester Retires Danish Qureshi Named President in Addition to Role as Chief Operating Officer SCOTTSDALE, Ariz., September 8, 2022 LifeStance Health (NASDAQ: LFST), one of the nation s
Read more →-LFST
Aug 9, 2022▼ -9.5%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Second Quarter 2022 Results SCOTTSDALE, Ariz. –
Investor Relations Contact VP of Investor Relations investor.relations@lifestance.com LifeStance Reports Second Quarter 2022 Results SCOTTSDALE, Ariz. August 9, 2022 LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healt
Read more →-LFST
May 23, 2022LIFESTANCE HEALTH NAMES DANISH QURESHI AS CHIEF OPERATING OFFICER, EFFECTIVE JULY 1, 2022 Gwen Booth Retiring from COO Role; Appointed as Executive Director, LifeStance Health Foundation
LIFESTANCE HEALTH NAMES DANISH QURESHI AS CHIEF OPERATING OFFICER, EFFECTIVE JULY 1, 2022 Gwen Booth Retiring from COO Role; Appointed as Executive Director, LifeStance Health Foundation SCOTTSDALE, Ariz. May 23, 2022 LifeStance Health (NASDAQ: LFST), one of the nation s larges
Read more →-LFST
May 9, 2022▼ -8.3%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports First Quarter 2022 Results SCOTTSDALE, Ariz. –
Investor Relations Contact VP of Investor Relations investor.relations@lifestance.com LifeStance Reports First Quarter 2022 Results SCOTTSDALE, Ariz. May 9, 2022 LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental health ca
Read more →-LFST
Mar 10, 2022▼ -8%on this news
Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2021 Results SCOTTSDALE, Ariz. –
Investor Relations Contact VP of Investor Relations investor.relations@lifestance.com LifeStance Reports Fourth Quarter and Full Year 2021 Results SCOTTSDALE, Ariz. March 10, 2022 LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatien
Read more →-LFST
Nov 8, 2021Monica Prokocki VP of Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Third Quarter 2021 Results Third Quarter 2021 Highlights (All results compared to prio
Investor Relations Contact VP of Investor Relations investor.relations@lifestance.com LifeStance Reports Third Quarter 2021 Results Third Quarter 2021 Highlights (All results compared to prior-year comparative period, unless otherwise noted) Revenue of $173.8 million increa
Read more →-LFST
Aug 11, 2021▼ -6.1%on this news· ran to -50% by day 1
Monica Prokocki VP of Investor Relations 425-279-8500 investorrelations@lifestance.com LifeStance Health Reports Second Quarter 2021 Results Second Quarter 2021 Highlights  Revenue of $
Investor Relations Contact VP of Investor Relations investorrelations@lifestance.com LifeStance Health Reports Second Quarter 2021 Results Second Quarter 2021 Highlights Revenue of $160.5 million increased $76.5 million or 91%1 compared to revenue of $38.6 million for the pe
Read more →Competitive Position
How LFST ranks across every disease it competes inCompetitive Position is a premium feature
See how LFST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial